source
- CellCentric secures $220 million Series D to advance multiple myeloma oral therapyCellCentric, a 22-year-old biotech operating across the Atlantic, announced it has closed a $220 million Series D financing round. The capital will be used to complete development and prepare for…
- Bayer agrees to acquire ophthalmology biotech Perfuse Therapeutics for $300 million upfrontBayer announced it will purchase Perfuse Therapeutics, a company focused on eye-disease treatments, for an upfront payment of $300 million. The acquisition includes Perfuse's mid-stage program that…